50 results about "Tumour immunotherapy" patented technology

The invention relates to a genetically modified mesenchymal stem cell (MSC) and medical use thereof in the treatment of tumours, said MSC comprising one or more exogenous nucleic acid molecule(s), wherein said exogenous nucleic acid molecule(s) comprise a region encoding one or more immune response-stimulating or immune response-modulating cytokine(s) operably linked to a promoter or promoter / enhancer combination. The invention encompasses the use of said cells in modulating the tumour microenvironment in order to attract immune effector cells and facilitate their activation and / or adoption of a memory phenotype. One aspect of the invention relates to the use of said cells in anti-tumour treatment comprising the combined administration of said mesenchymal stem cells with anti-tumour immunotherapies, such as checkpoint inhibitors, immune cells, for example T cells, such as T cells with artificial T cell receptors, for example a chimeric antigen receptor (CAR-Ts) or exogenous T-Cell Receptor (TCR) transduced cells, NK cells or macrophages / monocytes, or a cancer vaccine.

The invention relates to the field of gene editing and tumor immunotherapy. Specifically, the present invention relates to a method for preparing a modified T cell, such as a CAR-T cell, by gene editing, and the modified T cell prepared by the method and application thereof.

The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

Provided is a novel means for activating an immune response in tumor immunotherapy in which an immune checkpoint inhibitor is used. An immune-checkpoint-inhibitor antitumor effect potentiator having probiotics and prebiotics as active ingredients.

The invention relates to mesenchymal stem cells (MSCs) for use in the treatment of a tumor, wherein said treatment comprises the combined administration of said mesenchymal stem cells with an anti-tumor immunotherapy, and wherein said MSCs do not comprise exogenous nucleic acids that encode immune response-stimulating cytokines. In a preferred embodiment the invention relates to the use of said MSCs in the treatment of a tumor and / or malignant disease, wherein the anti-tumor immunotherapy for combined administration comprises the administration of a cellular immunotherapy, preferably chimericantigen receptor (CAR) T cells, wherein said T cell receptor binds specifically to a tumor-associated antigen, and the mesenchymal stem cells are not genetically modified.

The invention provides a method for constructing an immune-sound synovial sarcoma xenograft mouse model, which includes the cultivation of the P0 generation: first resuscitating the tumor tissue block of a synovial sarcoma patient stored in a liquid nitrogen environment, and then under aseptic conditions It was transplanted into immunodeficient mice; normal immune mice were pretreated with cyclosporine; culture of Px generation: the tumor tissue pieces grown in any generation of mice from P0 to Px‑1 generation were inoculated into the above-mentioned From the mice pretreated with cyclosporine, the Px generation mice were formed; the cultivation of the Py generation: take the synovial sarcoma tumor tissue pieces grown in any generation of mice from the Px generation to the Py-1 generation above and inoculate them into normal immune cells. In the mouse body, until the tumor tissue grows in the body, the culture of the Py generation is completed. The invention improves the problem that the traditional PDX model has no immune system, provides an in vivo model for the research of tumor immunotherapy, and broadens the application range of the PDX model.

The invention belongs to the fields of tumor immunotherapy and molecule immunology, and particularly relates to a humanized antihuman CTLA4 monoclonal antibody. The invention further relates to a preparation method and application of the humanized antihuman CTLA4 monoclonal antibody. Particularly, the humanized antihuman CTLA4 monoclonal antibody provided by the invention has high substantivity and high specificity for CTLA4, can stimulate T cells to secrete cytokine, for example, immunization negative regulation of the CTLA4 can be specially removed, and T cell cytokine can be activated. Thefunctional humanized antihuman CTLA4 monoclonal antibody provided by the invention can block a CTLA4 signal route to activate the T cells, and further the purpose of tumor immunotherapy is realized.